antiandrogens/fatigue

Koblingen er lagret på utklippstavlen

Velg sorteringstype

Side 1 fra 54 resultater

Antiandrogen monotherapy: indications and results.

Bare registrerte brukere kan oversette artikler

Logg inn Registrer deg

Many patients with prostate cancer for whom hormonal therapy is indicated are still physically and sexually active; quality of life is therefore a vital issue when considering treatment options. Traditional castration-based therapies, although effective, have implications with respect to quality of

Effects of the pure antiandrogen RU 23.903 (anandron) on sexuality, aggression, and mood in male-to-female transsexuals.

Bare registrerte brukere kan oversette artikler

Logg inn Registrer deg

Sexuality, aggression, and mood were investigated in 14 presurgical male-to-female transsexuals, undergoing antiandrogenic treatment with anandron, a pure antiandrogen. Subjects were given a test battery the morning prior to treatment onset and after 8 weeks of treatment. In addition they were

Influence of a six month endurance exercise program on the immune function of prostate cancer patients undergoing Antiandrogen- or Chemotherapy: design and rationale of the ProImmun study.

Bare registrerte brukere kan oversette artikler

Logg inn Registrer deg

BACKGROUND Exercise seems to minimize prostate cancer specific mortality risk and treatment related side effects like fatigue and incontinence. However the influence of physical activity on the immunological level remains uncertain. Even prostate cancer patients undergoing palliative treatment often

Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma.

Bare registrerte brukere kan oversette artikler

Logg inn Registrer deg

BACKGROUND Although antiandrogen withdrawal has moderate efficacy in patients with hormone refractory prostate carcinoma (HRPC), the effect of the simultaneous suppression of adrenal androgens with ketoconazole at the time of antiandrogen withdrawal is not known. METHODS Twenty consecutive patients

Hormone therapy of prostate cancer: is there a role for antiandrogen monotherapy?

Bare registrerte brukere kan oversette artikler

Logg inn Registrer deg

Androgen suppressive maneuvers still represent the gold standard for prostate cancer patients. However, they are associated with side effects (fatigue, sexual impotence, hot flushes, anemia, anxiety, depression and osteoporosis) all of which have a negative impact on quality of life. Nonsteroidal

Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.

Bare registrerte brukere kan oversette artikler

Logg inn Registrer deg

BACKGROUND Non-steroidal antiandrogens and castration are the main therapy options for advanced stages of prostate cancer. However, debate regarding the value of these treatment options continues. OBJECTIVE To assess the effects of non-steroidal antiandrogen monotherapy compared with luteinising

Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer.

Bare registrerte brukere kan oversette artikler

Logg inn Registrer deg

OBJECTIVE ARN-509 is a novel androgen receptor (AR) antagonist for the treatment of castration-resistant prostate cancer (CRPC). ARN-509 inhibits AR nuclear translocation and AR binding to androgen response elements and, unlike bicalutamide, does not exhibit agonist properties in the context of AR

Enzalutamide: a novel antiandrogen for patients with castrate-resistant prostate cancer.

Bare registrerte brukere kan oversette artikler

Logg inn Registrer deg

Enzalutamide (MDV3100, Xtandi, Medivation\Astellas) is an oral inhibitor of androgen receptor signaling that blocks androgen receptor interaction, inhibits translocation of the androgen receptor to the nucleus, impairs androgen receptor binding to DNA, and inhibits coactivator recruitment and

Efficacy, Prognostic Factors, and Safety Profile of Enzalutamide for Non-metastatic and Metastatic Castration-Resistant Prostate Cancer: A Retrospective Single-Center Analysis in Japan

Bare registrerte brukere kan oversette artikler

Logg inn Registrer deg

Background: Enzalutamide is a novel, non-steroidal anti-androgen that has demonstrated excellent anti-tumor activity for both non-metastatic and metastatic castration-resistant prostate cancer (nmCRPC and mCRPC) patients, and that is

A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.

Bare registrerte brukere kan oversette artikler

Logg inn Registrer deg

BACKGROUND Phosphatase and tensin homologue (PTEN) loss is common in advanced prostate cancer, leading to constitutive activation of the PI3 kinase pathway. Temsirolimus blocks mammalian target of rapamycin (mTOR)/target of rapamycin complex 1 (TORC1), a key signaling node in this pathway; its

Bicalutamide-induced hepatotoxicity: A rare adverse effect.

Bare registrerte brukere kan oversette artikler

Logg inn Registrer deg

METHODS Male, 81 FINAL DIAGNOSIS: Prostate cancer Symptoms: Anorexia • dark urine • joundice • letargy METHODS Casodex Clinical Procedure: - Specialty: Oncology. OBJECTIVE Adverse events of drug therapy. BACKGROUND Bicalutamide is a nonsteroidal anti-androgen used extensively during the initiation

Combination Chemohormonal Therapy in Metastatic Salivary Duct Carcinoma

Bare registrerte brukere kan oversette artikler

Logg inn Registrer deg

BACKGROUND Salivary duct carcinoma (SDC) is a rare, aggressive head and neck cancer with frequent metastases. Current treatment options for recurrent or metastatic SDC include targeted anti-androgen therapy, HER2-targeted therapy, or systemic chemotherapy. We report the first use of a combination

Use of cyproterone acetate in prostate cancer.

Bare registrerte brukere kan oversette artikler

Logg inn Registrer deg

Cyproterone acetate is a progestational antiandrogen with potent antigonadotropic activity that results in rapid suppression of serum testosterone. Used as a single agent, cyproterone acetate yields a total androgen blockade. It may be combined with low-dose diethylstilbestrol, orchiectomy, or LHRH

Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer.

Bare registrerte brukere kan oversette artikler

Logg inn Registrer deg

OBJECTIVE To exploit the favorable dose intensity and safety profile of weekly paclitaxel, we conducted a Phase I trial of paclitaxel by 3-hour infusion in combination with estramustine phosphate (EM) in men with hormone-refractory prostate cancer (HRPC). The antimicrotubule drug combination of

A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases.

Bare registrerte brukere kan oversette artikler

Logg inn Registrer deg

BACKGROUND BMS-275291 is a selective matrix metalloproteinase inhibitor (MMPI) that does not inhibit sheddases implicated in the dose-limiting arthritis of older MMPIs. We conducted a randomized phase II trial of two doses of BMS-275291 (1,200 versus 2,400 mg) in hormone-refractory prostate cancer

Tidligere
1
2
3
4
Neste

Bli med på
facebooksiden vår

Herbal & Natural Medicine

Den mest komplette databasen med medisinske urter støttet av vitenskap

Fungerer på 55 språk
Urtekurer støttet av vitenskap
Urtegjenkjenning etter bilde
Interaktivt GPS-kart - merk urter på stedet (kommer snart)
Les vitenskapelige publikasjoner relatert til søket ditt
Søk medisinske urter etter deres effekter
Organiser dine interesser og hold deg oppdatert med nyheter, kliniske studier og patenter

Skriv inn et symptom eller en sykdom og les om urter som kan hjelpe, skriv en urt og se sykdommer og symptomer den brukes mot.
* All informasjon er basert på publisert vitenskapelig forskning